Question 1

What is Non-racemic MDMA?

Accepted Answer

Non-racemic MDMA is a Other.

Question 2

How often does Non-racemic MDMA appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was Non-racemic MDMA first tracked by Ergen?

Accepted Answer

First tracked on Jul 06, 2026.

Question 4

When was Non-racemic MDMA last mentioned in news?

Accepted Answer

Last active on Jul 06, 2026.

Question 5

What is Non-racemic MDMA's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Non-racemic MDMA in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Non-racemic MDMA?

Accepted Answer

PharmAla ALA-002 Manufacturing, Patent, Australia (Jul 06, 2026, 7 articles).

Question 8

How did the "PharmAla ALA-002 Manufacturing, Patent, Australia" event impact Non-racemic MDMA?

Accepted Answer

Non-racemic MDMA is PharmAla Biotech Holdings's lead drug candidate, for which GMP manufacturing of drug substance is complete, an Australian patent has been granted, and commercialization rights in Australia have been exercised by Cortexa.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.